Morphine: Difference between revisions
No edit summary |
Elcatracho (talk | contribs) |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[ | *Type: [[Opioids]] | ||
*Dosage Forms: 5, 10, 15, 20, 30, 45, 50, 60, 75, 80, 90, 100, 120, 200, 0.5/ml, 1/ml, 2/ml, 4/ml. 5/ml, 8/ml, 10/ml, 15/ml, 25/ml, 50/ml, | *Dosage Forms: 5, 10, 15, 20, 30, 45, 50, 60, 75, 80, 90, 100, 120, 200, 0.5/ml, 1/ml, 2/ml, 4/ml. 5/ml, 8/ml, 10/ml, 15/ml, 25/ml, 50/ml, | ||
*Common Trade Names: Astramorph, AVINza, Duramorph, Infumorph, Kadian, MS contin | *Common Trade Names: Astramorph, AVINza, Duramorph, Infumorph, Kadian, MS contin | ||
Line 7: | Line 7: | ||
*Acute pain (Moderate to severe): | *Acute pain (Moderate to severe): | ||
**Oral: 10-30mg q4hr PRN | **Oral: 10-30mg q4hr PRN | ||
**IM: 5-15mg | **IM: 5-15mg | ||
**IV: | ***Typically not recommended due to erratic absorption | ||
***If utilized, no more than one IM dose should be given, due to the danger of "stacking" doses (may lead to respiratory compromise) | |||
**IV: 0.1 mg/kg bolus followed by 0.05 mg/kg q15-20 min until pain controlled | |||
***Hold further doses for respiratory depression | |||
***Dosed according to ideal body weight | |||
***AMI: 4-8mg q5-15min PRN | ***AMI: 4-8mg q5-15min PRN | ||
***Critically ill: 2-4mg q1-2hr or 4-8mg q3-4hr PRN | ***Critically ill: 2-4mg q1-2hr or 4-8mg q3-4hr PRN | ||
Line 22: | Line 26: | ||
***Continuous microinfusion: 0.2-10mg over 24 hours (max ~20mg) | ***Continuous microinfusion: 0.2-10mg over 24 hours (max ~20mg) | ||
**Rectal: 10-20mg q3-4hr | **Rectal: 10-20mg q3-4hr | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Children >6months and <50kg | *Children >6months and <50kg | ||
Line 48: | Line 53: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Circulatory depression, shock, cardiac arrest | *Circulatory depression, [[shock]], [[cardiac arrest]] | ||
*Bradycardia, hypotension | *[[Bradycardia]], hypotension | ||
*CNS depression, sedation | *[[CNS depression]], sedation | ||
*Apnea, respiratory arrest/depression | *Apnea, respiratory arrest/depression | ||
*Anaphylaxis, laryngospasm | *Anaphylaxis, laryngospasm | ||
Line 64: | Line 69: | ||
*Hypoxia | *Hypoxia | ||
*Histamine release, urticaria | *Histamine release, urticaria | ||
*Afib, tachycardia, edema, chest pain | *[[Afib]], [[tachycardia]], edema, [[chest pain]] | ||
*Abdominal pain | *Abdominal pain | ||
Latest revision as of 20:12, 20 February 2021
General
- Type: Opioids
- Dosage Forms: 5, 10, 15, 20, 30, 45, 50, 60, 75, 80, 90, 100, 120, 200, 0.5/ml, 1/ml, 2/ml, 4/ml. 5/ml, 8/ml, 10/ml, 15/ml, 25/ml, 50/ml,
- Common Trade Names: Astramorph, AVINza, Duramorph, Infumorph, Kadian, MS contin
Adult Dosing
- Acute pain (Moderate to severe):
- Oral: 10-30mg q4hr PRN
- IM: 5-15mg
- Typically not recommended due to erratic absorption
- If utilized, no more than one IM dose should be given, due to the danger of "stacking" doses (may lead to respiratory compromise)
- IV: 0.1 mg/kg bolus followed by 0.05 mg/kg q15-20 min until pain controlled
- Hold further doses for respiratory depression
- Dosed according to ideal body weight
- AMI: 4-8mg q5-15min PRN
- Critically ill: 2-4mg q1-2hr or 4-8mg q3-4hr PRN
- Continuous infusion IV, SC: 0.8-10mg/hr (up to 80mg/hr)
- Critically ill: 2-30mg/hr
- PCA 0.5-2.5mg q5-10min PRN
- Epidural (Preservative free)
- Single dose: 30-100mcg/kg
- Continuous infusion: 0.2-0.4mg/hr
- Continuous microinfusion: 3.5-10mg over 24hrs, titrate to effect (max ~30mg)
- Intrathecal (Preservative free)
- Single dose: 0.1-03.mg
- Continuous microinfusion: 0.2-10mg over 24 hours (max ~20mg)
- Rectal: 10-20mg q3-4hr
Pediatric Dosing
- Children >6months and <50kg
- Acute pain (Moderate to severe)
- Oral: 0.15-0.3mg/kg q3-4hr PRN
- IM, SC: 0.1-0.2mg/kg
- IV: 0.05-0.3mg/kg q3-4hr PRN (not to exceed 10mg/dose)
- Continuous infusion: 10-30mcg/kg/hr
- PCA 0.01-0.03mg/kg/dose and 0-0.03mg/kg/hr
Special Populations
- Pregnancy Rating: C
- Lactation: Enters breast milk
- Renal Dosing
- CrCl 10-50: 75% of normal dose
- CrCl <10: 50% of normal dose
- HD: Child 50%, adult no adjustment
- PD: Child 50%
- CRRT: Child and adults 75%
- Hepatic Dosing: No adjustment generally (cirrhosis can consider dose adjustment)
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Circulatory depression, shock, cardiac arrest
- Bradycardia, hypotension
- CNS depression, sedation
- Apnea, respiratory arrest/depression
- Anaphylaxis, laryngospasm
Common
- Dependence
- ADH release, hypogonadism
- Drowsiness, dizziness, confusion, headache
- Pruritis
- Xerostomia, constipation, vomiting
- Urinary retention
- Pancytopenia
- Weakness
- Hypoxia
- Histamine release, urticaria
- Afib, tachycardia, edema, chest pain
- Abdominal pain
Pharmacology
- Half-life: Immediate release 2-4hrs; Avinza 24hrs; Kadian 11-13hrs
- Metabolism: Hepatic
- Excretion: Urine and feces
- Mechanism of Action:
- Binds to opioid receptors in CNS
- Inhibits ascending pain pathways
- Alters perception and response to pain
- Produces CNS depression